The RES-Q study is a new clinical trial focused on developing innovative treatments for Non-Small Cell Lung Cancer (NSCLC). This research aims to address the significant challenges in treating patients after initial therapies, like immune checkpoint inhibitors, have not been successful.
Addressing a Critical Need in Lung Cancer Treatment
Non-Small Cell Lung Cancer can be a difficult disease to treat, with limited options for patients whose cancer no longer responds to standard therapies. Current treatments often come with modest survival benefits and high toxicity. The RES-Q study was initiated to address this urgent unmet medical need by exploring a new therapeutic approach for patients with advanced NSCLC.
Our Approach
The primary goal of the treatment regimen in this study is to enhance the body’s natural defenses against cancer. The approach is designed to maximize immune cell death (ICD) of cancer cells while simultaneously augmenting and maintaining the body’s innate and adaptive immune responses.
Enrollment Status
This study is currently enrolling patients. To learn more about AMPLITUDE and how you can join contact our research office at (314) 289-7690.